Literature DB >> 6953740

Clinical pharmacokinetics of methadone.

M I Nilsson, U Meresaar, E Anggård.   

Abstract

Studies with single doses of methadone have shown that the oral biological availability is 79 +/- 21%, range 41-99%. The rate of elimination is mostly due to metabolic clearance. Below a urinary pH of 6, renal clearance becomes of quantitative importance. In five subjects treated with ammonium chloride (acidic urine), the plasma half-life of methadone was found to be 19.5 +/- 3.6 h. When treated with sodium bicarbonate the same subjects had plasma half-lives of 42.1 +/- 8.8 h. During continuous treatment with methadone, cellular tolerance may occur and in some subjects also metabolic tolerance. In treatment of severe cancer pain such adaptive changes in methadone pharmacodynamics and pharmacokinetics are best managed by a regimen involving a fixed dose but a flexible and patient-controlled dosage interval.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6953740     DOI: 10.1111/j.1399-6576.1982.tb01850.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand Suppl        ISSN: 0515-2720


  17 in total

1.  Applying legal risk management to the clinical use of methadone.

Authors:  James O'Donnell; F Randy Vogenberg
Journal:  P T       Date:  2011-12

2.  Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.

Authors:  Feng Yang; Xianping Tong; D Gail McCarver; Ronald N Hines; Daniel A Beard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-07       Impact factor: 2.745

3.  [Not Available].

Authors:  J Jage
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

Review 4.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 5.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 6.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Pharmacokinetics of opioids in renal dysfunction.

Authors:  G Davies; C Kingswood; M Street
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 8.  Methadone for Pain Management: A Pharmacotherapeutic Review.

Authors:  Denise Kreutzwiser; Qutaiba A Tawfic
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

9.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.